Body Weight Is 40-70% Heritable. Here's What That Doesn't Mean | Giles Yeo | 222
1 hr 34 minAudio
Send us Fan Mail Short Summary: The science of obesity and appetite regulation, blending genetics and neurobiology with practical insights About the guest: Giles Yeo, PhD is a professor of molecular neuroendocrinology at the University of Cambridge. He leads a lab studying obesity and appetite regulation. Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Full transcript and other information on Substack. Episode Summary: Nick interviews Dr. Giles Yeo about the genetics and neurobiology of obesity, starting with the discovery of leptin in the obese mouse model, detailing its role in appetite regulation via the hypothalamus, and discussing GLP-1 drugs like Ozempic for weight loss. It delves into how genetic factors, like the leptin-melanocortin pathway, influence hunger, the heritability of body weight, and societal factors driving the obesity epidemic, emphasizing the interplay of biology and environment. Key Takeaways: Leptin, discovered through the obese mouse, signals fat levels to the brain, but its absence causes severe obesity and infertility, as seen in rare human mutations. The hypothalamus, a key brain region, senses hormones like leptin and GLP-1, balancing hunger and satiety through POMC (anorexigenic) and AgRP (orexigenic) neurons. Body weight heritability is 40-70% at the population level, but this does not mean that 40-70% of someone’s body fat composition is due to genetic factors outside human control. Dr. Yeo unpacks how to think about it. GLP-1 drugs (e.g., Ozempic) mimic gut hormones to reduce appetite, offering some people 15-25% weight loss, but require long-term safety monitoring. According to Dr. Yeo, obesity reflects energy imbalance, but nutritional density matters more than calorie counting for health, and societal changes are needed to prevent it. Related episode: M&M #132: Obesity Epidemic, Diet, Metabolism, Saturated Fat vs. PUFAs, Energy Expenditure, Weight Gain & Feeding Behavior | John Speakman *Not medical advice. Support the show Support my work: Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly. Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health. For all the ways you can support my efforts.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Nick JikomesWhether food, drugs or ideas, what you consume, influences, who you become. On the mind and matter podcast, we learn together from the best scientists and thinkers alive today about how your mind body reacts to what you feed it before starting mind and matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience, where I focused on neuro endocrinology and the neurobiology of behavior, and before that, I specialized in molecular developmental and evolutionary genetics. I use my scientific background to help parse and translate the information that guests share on the podcast. In addition to the podcast, I write long form written content inspired by the show, where I integrate what I've learned across episodes. I also have a free weekly newsletter where I provide you with upcoming guests, share links and provide commentary on scientific studies and research that I'm reading, and more visit Mind and matter.substack.com. To find all of my content foreign. Thank
Giles Yeoyou so much for having me, Nick, do you want to start off by just telling everyone a little bit about who you are and what your lab studies? So I am, I am a geneticist. Well, I train as a geneticist, but I'm a professor of Molecular neuroendocrinology here at the University of Cambridge in the UK, where we study, we study two things. We study the genetics of body weight. On one end, the spectrum happens to sit obesity and how the brain controls food intake. So those are the two elements that we study.
Nick JikomesAnd when we think about the genetics of, you know, obesity, metabolism, stuff related to that, probably the most famous place people often start is this famous mouse model that had a mutation that resulted in extreme obesity. Can you start us off by just talking about that mouse model? What is the phenotype and what is the genotype there?
Giles YeoSo the phenotype, well, the mouse model was called the obese mouse lacking because the mouse was obese. So a disappointing failure of imagination, pardon me, a disappointing failure of imagination, a naturally occurring mouse at the Jackson labs in Maine and identified actually in the late 40s, and so it took a while. So people were studying this mouse. It was called the obese mouse for that for that reason, it was severely obese. It was in homozygous state. It was infertile. It was a recessive disorder, so that, in other words, the heterozygous mice were of normal weight. But it was only in the mid 1994 actually, so the sort of the early 90s that the Friedman lab at the Rockefeller University in New York, you know, in the age of molecular biology, identified the mutation causing this, this obesity, and that was a mutation in the gene called leptin. And so the OB mouse, and this was, in effect, the first real molecular handle that we within the whole community got, that body weight was not simply a matter of willpower, shall we say? So, this mouse lacked a hormone leptin, which is produced from fat. We'll come back to that, but, but lack the hormone leptin and and as a result, was severely obese. And from there came the whole concept that we sort of work on today with regards to body weight regulation and feeding regulation, and that of circulating hormones in the body that reflects your nutritional status, either long term from fat or short term from from your gastrointestinal tract, that sends signal to the brain, and your brain then responds, translates and integrates these long and short term signals and then influences your next interaction with a menu, with a refrigerator, you know, or with a restaurant. So, so that, in essence, is that OB mouse, the obese mouse.
Nick JikomesSo this mouse has this homozygous for recessive mutation in what we eventually figure out is the leptin gene, the gene encoding leptin, which is an important hormone we'll discuss. This mouse is severely obese. So if you look at pictures online, you know, I mean, it's
Giles Yeospherical. It's a spherical it looks like a tennis ball, except it has whiskers on one end and tail in the other, so
Nick Jikomesseverely obese. And there's other phenotypes that maybe we'll get to at some point. You mentioned one of them, which is infertility. So it's not just adiposity, where something is happening here, there's other things going on. It appears was this mouse the way. That we discovered leptin, or did we already know about leptin in some capacity? No, we didn't
Giles Yeoknow about leptin. So this mouse was the way we discovered leptin, now in the with the OB, O, B mouse, and actually it had a phenocopy. So there was another mouse called the DB, DB mouse, or the diabetes mouse. That was another naturally occurring mouse. This was identified in the early 50s, in which people used non molecular tools to try and work out what the hell was going on. Why? Why were these mouse Why were these mice severely obese? Okay, so the OB mice was obese mouse, the DB, DB mouse was a diabetic mouse, but in effect, they were, you know, copies of each other. They were severe obese and and what happened was scientists were doing these weird experiments called parabiosis. I don't even know what a parabiosis experiment is, but parabiosis is a reverse siamese twin operation, where what you do is you and not allowed to do today, by the way, in today's climate of, you know, ethics and stuff, but in the 50s or 60s. And so what they did, scientists did, was to sort of merge the circulations of mice that were severely obese, ob mice with normal mice, DB DB mice, diabetic mice with normal mice, and then OB and DB DB mice. And what they found was that if you actually stuck an OB mouse to a skinny normal mouse, the the OB mouse lost weight, okay. And then when they stuck a db, db mouse, a diabetes mouse, to the a normal size mouse, the normal size mouse stopped eating and died. Okay, so something,
Nick Jikomeswhen something in the circulation is traveling between them, especially what this means
Giles Yeoexactly. And then they did the same experiment with the OB and the DB DB and ultimately this then had the hypothesis that there was a circulating hormone that was missing in the obob mouse and a receptor that was a missing in the DB DB mouse. And you know, it's a real stretch, but it turned out to be true, because the OB mouse turned out to have a mutation in leptin Okay, which is the hormone, whereas the DB, DB mouse turned out to have a mutation in leptin receptor, okay, which is the which is the receptor. And it was only in the age of molecular biology that they then found out what those were. So the concept of a circulating hormone and a receptor was floating about, yes, the identity of it was until 1994 I see,
Nick JikomesI see, so people have these ideas, but it wasn't till certain tools were developed that you could actually figure out, okay, this is a circulating hormone and a receptor. So this leptin mouse has mutation in the leptin gene encoding the actual Leptin hormone itself, as opposed to the receptor for leptin. But so you get this obesity phenotype, this infertility phenotype, really striking phenotype, where is the leptin receptor concentrated in the brain and body? So
Giles Yeothe as it turns out, the letter receptor is really quite complicated, and we know we know really a lot about one subtype of it, which is the signaling form of it, what we call the long form of the leptin receptor. And that the leptin receptor, in this long form is a typical tyrosine kinase receptor. Okay, so you bind it, and then there's phosphorylation of tyrosine kinases in in the cytoplasm, inside the cell, and but there, there are a whole bunch of other shorter forms of leptin receptors, and some even say circulating forms of of leptin receptors that we actually have no idea what they do. And so the circulating and short forms are present in many, many parts of the body. The long form, the one with the tyrosine kinase receptors, are primarily neuronal within, within the brain, I see. And so they are. They're everywhere in the brain. They're concentrated in the hypothalamus of the brain, which is, for those of you who don't know where, that is the bridge of your nose, base of the brain, and it sits right above the pituitary, and that's where it tends to be concentrated. But it's expressed throughout the brain, the leptin receptor. And
Nick Jikomesso when you see that, so there's multiple versions of the leptin receptor, are these isoforms of the same gene, or
Giles Yeoisoforms of the same gene splicing. These are all splicing variations
Nick JikomesI see. So one gene can create multiple versions of the leptin receptor, but there's one form that predominates, or that we at least know the most about. It's found in multiple places, but it's found in the brain, concentrated in the hypothalamus, but located in many, many parts of the brain, and it's a particular type of receptor, and obviously this is what leptin binds to. So something about leptins ability to bind this receptor is what's disrupted in that OB, ob mouse,
Giles Yeothe OB mouse, had a mutation in leptin, which in effect stops it from binding. Yeah, I
Nick Jikomessee. I see. Okay, so the end result, so when leptin can't bind effectively to the leptin receptor, the result is this dramatic obesity phenotype. This receptor is located in the brain, in the hypothalamus, which was already known at that time to be crucial for things like feeding and metabolism in different ways. So so it starts to point us to leptins action in the hypo. Thalamus before we get there, literally, I want to give people a basic sense for the hypothalamus in mammals. So you mentioned where it's located. It's essentially in the middle of our head, right behind our eyes, in sort of the center, right above the pituitary. Can you give us a sense for sort of the size and structure of the hypothalamus down to the cellular level, as opposed to other parts of the brain here. So I'm thinking of something like the cerebral cortex. How does the basic architecture of that part of the brain differ from this part of the brain?
Giles YeoSo the hypothalamus, okay, size first in humans anyway, right? In mice, it's a lot smaller. Clearly, in humans, it is about the size of your thumbnail and is shaped like an almond, okay? And it says, and it plays a role. In terms of its role. It plays a role in all forms of homeostasis. So balance includes energy balance, which is what we're talking about, body weight balance, but it plays a role in salt balance, temperature balance, stress, sexual, you know, reproduction, circadian rhythms. It plays a role in a number of different things that your body has to keep your body in balance, so homeostasis. But we're talking about, we're talking about body weight today, obviously now, as a part of the brain, it is a relatively is not the most ancient part of the brain, that's the that's the brain stem, but it's one of the most ancient parts of the brain, and it is definitely the most complex part of the brain, okay? Because what happens is it is formed of these groups of cells called nuclei. So as opposed to the nuclei within a cell, they're sort of nuclei of cells, shall we say, within hypothalamus. And it is the most heterogeneous part of the brain in terms of the number of cell types that are there. That's the first thing. The second thing is that it is it bristles with receptors because it acts as a it because of where it sits at the base of the brain. It senses circulating hormones, nutritional cues, which is what we're talking about, but a whole bunch of other things, stress hormones, sex hormones, all these hormones as well. So it's bristling with the receptors. It is also the part of the brain that secretes the most hormones, neuro hormones and neuropeptides. So with all that in place, if you go to some other part of the brain, the only part of the brain that perhaps is sort of similar to it is probably the hindbrain, but that also sits sort of as a sensor area. The rest of the brain is complex. Look, it is very complex, okay, particularly the higher order. But they're not as heterogeneous. They're not necessarily uh organized into nuclei in in as such, certainly not as many as they are within hypothalamus. So, so that really is, it is a very it's the most complex part of the brain,
Nick Jikomesyeah. So, So to reiterate some of that, so a it's an ancient part of the brain. So the hypothalamus exists basically in all animals, and it's going to have similar characteristics across all of them. There's going to be differences as well. And we might talk about some of the human differences compared to rodents, say. But the the basic features of the hypothalamus have been around for a very, very long time. Yeah,
Giles Yeothey're sort of versions of some of the neuronal types within hypothalamus that exists all the way down to worms. Well, the worms don't have a hypothalamus, per se, but the sort of prototypes of these, of these neurons were already there in C elegans. And,
Nick Jikomeswell, yeah. And so you said, in a human, it's roughly the size of the thumbnail. It's located sort of in the center base of the brain, so the cerebral cortex, or if you just think about it, the wrinkly outer layer part of our brain, it's much, much bigger. And you also said, so, so it's evolutionarily old. There's going to be a lot of conserved ancient functionality here that's common across animals. It's it's got an interesting architecture at the cellular level. So you said there's more cell types here. There's more cell type diversity here than probably any part of the brain, other than maybe the hindbrain. So if we were to look at, say, the cerebral cortex and sort of count or use molecular techniques to identify distinct types of cells, there's way more diversity in the hypothalamus than other parts of the brain, and based on where it's positioned and based on some other things we're talking about, what we're going to talk about it is it's connected to a lot of parts of the brain, and it's also sort of a sensor integrator of signals, not just from other neurons, but as we sort of maybe hinted at the beginning, things like hormone signals in the blood as well,
Giles Yeoabsolutely. So. So it act, it acts as a sensor for many hormones within the context of body weight. It's probably safe to say it's a fuel sensor within the context of body weight. Yeah.
Nick JikomesAnd so talk a little bit about this hormone sensing capability and what. So normally, when we talk about the brain, we talk about the blood brain barrier and how it exists and how it's preventing just anything from getting into the brain from the bloodstream. Nonetheless, there are parts of the brain where neurons can sample pretty much directly from the bloodstream, or at least the blood brain barrier is weakened compared to other parts of the brain. Can you talk about that a little bit with respect to the hypothalamus?
Giles YeoSo. Hypothalamus and hindbrain actually are both what we call circumventtricular organs and and that means that they it's not weak, I think it's the designs, rather, rather than a week in which they are fenestrated. Okay, so in other words, there are, there is the ability of peripheral hormones to make it into the brain. This is not, it doesn't go through by diffusion. I want to point out, right? It is a it is a regulated process in which in this parts of the brain, they're able these hormones and many other things, and many other things, including nutrients themselves, managed to actually get across this layer and into the hypothalamus and in the hindbrain as well, where the hypothalamus, therefore samples and then I is able to use the information for for command and control,
Nick Jikomesso So hormones and nutrients can get, literally, get into the hypothalamus. It's not a passive process. This is supposed to happen, so to speak. It's, it's designed or involved this way. And
Giles Yeowe talked about evolve, that's right, not designed, yeah, evolve this way. I'm not a
Nick Jikomesdesign through a distributed, decentralized, natural process, so hormones obviously can get into the hypothalamus. Leptin is what we talked about at the beginning. What talk about, how is leptin? Well, actually, before we talk about what leptin is doing in the hypothalamus, where is it actually coming from? We know it gets to the hypothalamus from the bloodstream, but where's all of this leptin coming from originally?
Giles YeoSo leptin is produced exclusively from fat adipose tissue, and specifically the adipocytes. So in other words, you know, fat obviously has other has other stuff in it, but primarily are adipocytes. And so leptin is produced exclusively from adipocytes, and it circulates in proportion to the amount of fat that we have. So the more, the more fat you have, the more leptin you have. And the lesser fat you have, the less leptin you have. So it's secreted
Nick Jikomesfrom fat cells, and the more of them you have, the more leptin that's circulating. Okay, so it circulates. It gets up to the hypothalamus. It can get in there, because this is a circumventtricular organ, and certain hormones and other things can get into the hypothalamus. What's sort of going on next? What are the main cells or parts of the hypothalamus that are sensing leptin? And you know, at a high level, what is a high level of leptin actually signaling to
Giles Yeothe brain? Do we think so? A high level of leptin is signaling to the brain that you have a lot of fat, and a low level of leptin is signal to your brain. You don't have a lot of fat, but it extra out the entire spectrum. Okay, so in other words, so you you obviously it's a full it's a full spectrum because there's a concentration gradient. Now, what happens when it actually gets to the hypothalamus? And this is and, to be fair, I have to oversimplify it, because it's just too complex, and we don't know all of it, but when it gets to the brain, one of the things it does is it signals to a population of neurons called the POMC neurons, proopiomes at the occupied nucleus of hypothalamus, right at the very base. And then there, when leptin signals to leptin receptor expressing POM C neurons, prompt C is then, sort of post translationally modified, sort of chopped up, okay, by promo and COVID cases. And then they signal, they in turn, project to and signal to another part of the hypothalamus called the paraventry nucleus, just another part of the hypothalamus where melanocortin receptors exist and and because this pro hope melanocortin make melanocortin peptides which bind to melanocortin receptors. Now this whole pathway leptin, leptin receptor, proopium melanocortin Melano cotin receptors, is called the leptin melanocortin pathway because it's the namesake or the central leptin Lenox cotin pathway within within the brain. And put simply, this pathway acts as the fat sensor within our body. So your your brain senses amount of fat. And this is the key. This is the key pathway within our brain that senses how much fat we have. It's conserved. All mammals have this pathway. And most higher vertebrates who have a demonstrable fat pad will have have a demonstrable amount of fat that you can see. And way will have this pathway. So
Nick Jikomesleptin binds to leptin receptors in the hypothalamus. It can get in there because the hypothalamus is a circumvent particular organ and is essentially built to sample the bloodstream. One of the main targets within the hypothalamus are these palm C neurons, and this is part of the leptin melanocortin pathway. So basically, the OB, ob mouse that you told us about the beginning, it had a mutation in the leptin gene, and it was severely obese. It was, it was basically unable, that mouse was unable to sense its own body fat level, correct.
Giles YeoYes, yep, the signal between fat and brain broken. So the brain, in effect, thinks it has no fat, broadly speaking, because it has, because it can't sense the left and it says, oh shit, there's no there's no fat. I've got no fat, which is a bad thing, yes, because we're designed to have some fat in us. So
Nick Jikomesis it, you know? So, so how does this hook into other parts of this region of the. Hypothalamus, is it fair? So this is a fat sensor, and obviously this is going to tie into things like hunger and food intake. But do people think of this as like a satiety controlling circuit? Or, how do we think about that? That's
Giles Yeoan interesting question. I think when it was first discovered leptin, I want to say this could serve so it's the oldest. It's found in humans as well. But when, when it was first discovered, it was said to be a satiety hormone, I don't think it is a satiety hormone. It is a fat hormone. It is a how much fat Do you have hormone? Okay, but the crucial thing is, is designed to signal not over nutrition, because, from an too much fat, because, from an evolutionary perspective, we there was no pressure there. We never had too much the vast majority of evolution. We never had too much food, where we had to design an entire system
Nick Jikomesto tell forever an issue until, you know, blink of an eye ago, over
Giles Yeo30 exactly, literally, a brink of an I go like 30 years or 40 years or so. It's designed to let your brain know you have not enough fat, which means that you're starving. In effect, okay, just,
Nick Jikomesjust a starvation hormone, just to emphasize it for people, right? Not enough fat for basically all evolutionary history of animals was a very big, very frequent problem. Too much fat was essentially never a problem. And so the system evolved to reflect the fact that no fat was a problem, and too much fat essentially never was,
Giles Yeoexactly, and so, and so there was no there was no pressure. There is a pressure on total size. And we can get to that baby, and that was probably predator rise, you know. So you can you, you need to make sure you don't get too big. It's sort of like the peacock, right? The peacock can with this, with the silly tail. This is probably the maximum size it gets before it gets eaten. And so we do probably have a maximum size. But undoubtedly, the key selection pressure is starvation, having not enough having not enough fat.
Nick JikomesOkay, and then, so you said these, so these palm C neurons are a key type of neuron in the hypothalamus that are sensing the leptin, because they have the leptin receptor proopiomelanocortin. This is a peptide, as opposed to, say, a neurotransmitter. Can you talk a little bit about the difference between peptides and neurotransmitters and the significance of having the these neurons have peptides, and what that sort of enables them to maybe do. Okay,
Giles Yeoso when we think about the brain, there are two different ways that I'm simplifying, but there's two different ways that communicate. There is the wired connection, and the wired connection, which means that synapses are going and going to another synapse. And broadly speaking, they they communicate through these things called neurotransmitters and electrical impulses, alright? And so these include things like GABA includes things like glutamate, you know, it includes acetylcholine. A number of these transmitters that actually move stuff, but it's wired okay? So they come out. They come out actually, at the end of synapse, the synaptic gluttons, you know, which are projecting to Soma with the cell bodies. Now, the thing about neuropeptides, however, is it's almost a wireless connection because it's hormonal. It's neuro hormonal, but it's hormonal, which means that they can be released from the synapse, yes, but they can equally also be released from the cell body, like in like, like in other cells in our body, where there's a vesicle, it comes to the surface and it releases a hormone. The same thing can happen within the brain, and so it sort of can diffuse. Is a very, very strong word here, but the rate of signaling is very different. And g and kinetically is very it's very different because rather than really quick millisecond, microsecond impulses, you have to wait for the hormone to be released, move about, get to get to another cell. So that's the difference between the wire. One is wired, which is the neurotransmitter, and why is wireless?
Nick JikomesSo there's differences in the spatial and temporal dynamics of these different communication modalities. When you're talking about neurotransmitters and wired communication, it's like very fast millisecond to millisecond point to point communication between the wires, which are the neurons in this case. But when we're talking about these peptides that can be released from some neurons, it's a much sort of slower, lower resolution response. Essentially, it's
Giles Yeostill pretty quick, but it is, but it is far, far log scales, slower than neurotransmitters. Yeah.
Nick JikomesAnd I mean, is this? How do you think about this? Is this related to the fact that these neurons are, say, sampling hormones from the blood, and they need to. They don't merely need to do fast point to point communication. They need to do these sort of longer integrations of slower signals. I don't
Giles Yeothink they're mutually exclusive to each other, because I think probably when, and that's an interesting question, actually, why? Why there is a these two? I think, okay, let's. Step back, I get the feeling that there are two almost separate, different, separate types of ways that the that the that your neurons communicate, actually it's probably a third type we can get to that. Okay, that's the plasticity type as well. But with regards to sending stuff out, okay, I think this gives us more a finer ability to tweak the system. You need stuff that happens quickly. You need stuff that actually happens over a period of time, which I think this gives us the full sort of like spectrum of speeds of communication for different particular, different reasons. Okay, we need stuff that moves quickly so that we can, you know, we can stop things we can, you know, and calcium channels can open, and all kinds of things happen. But we also need things to tell us, you have this amount of fat in your body, okay? And that maybe is a, is a longer term sensing and sensing process. I, I mean, this is not my area of expertise. Can I please just stress the difference between, this, but this is what I think
Nick Jikomesso. So leptin can activate these neurons. Does when these neurons become active or they're made active, do animals? How does that change their feeding behavior?
Giles YeoSo there are two groups of these, melanica, I I neglected to mention another, another group of neurons. So when leptin comes up. Maybe we should do this. It signals to pump C neurons. And pump C neurons are anorexigenic, anorexia, not eating so. So in other words, when pump C neurons are activated you you tend to eat less. Okay, so the anorexogenic. Now, there is a counterpart set of melanocortin neurons in the brain called the AgRP neurons, agouti related peptide neurons, okay, and it's a long story why they call that, but there they act. They sit in the same part of the brain, the hypothalamus. They also express leptin receptors, but when they get activated the AgRP neurons, they encourage food intake, they are orexigenic, which is the opposite to anorexigenic. And so what happens is both of them signal to the melanocortin receptors, and they act as a gas pedal and break all right. And it's the tone of how much of pump c signal versus AGR AgRP signals on the melanocortin receptors, that sort of feather how much we eat. It's a very, very, very subtly tunable system, so it's not on or off. It literally is the ratio of AgRP signal to pump c signal, which then sets how much we are likely to eat in any given meal. So
Nick Jikomesyou got, you got two neural populations with basically opposing functions with respect to feeding. The AgRP neurons promote feeding the other, orexigenic, that's the technical term. And then the palm C neurons, that are sensing leptin, they are anorexigenic. And so these two have similar targets, and sort of the balance of activity between the two is a big part of what controls hunger and feeding levels. I would imagine you know, other than you know if the hypothalamus is this integrator of multiple signals, and obviously how hungry you should be, how much you should be eating, that's going to be related to how much fat is currently on your body, but it's gonna be related to other things as well. I would imagine that these cells are sensing directly or indirectly, other things, rather than the fat content of the body, such as, say, nutrients that are related to meal you may have just had or not had.
Giles YeoYes. So they sense also. They also have receptors for some of the gut hormones, for example, the GLP one receptors are present on pump C neurons, not all pumpkin neurons, but some pumpkin neurons, for example, they express the insulin receptor. Now insulin, we understand, famously, regulates our as an intermediary. It's important intermediary metabolism, particularly for for carbohydrate absorption, but actually all fuel absorption, but insulin also reflects long term fat mass and nutrients in of themselves. Okay, so, for example, glucose sensing or fat sensing or protein sensing even okay. So all of these, not all of these neurons have all of these receptors, but all of these receptors are present to some degree on these neurons, so the neurons really sense and integrate it, because we look when we eat or don't eat, it's a repertoire of hormones and nutrients and things that are released, and so it's designed to sort of dip a toe into The soup, yeah, and sense that.
Nick JikomesYeah. So this again, so this part of the hype, the hypothalamus is at the base of the brain, right above the brainstem, but the arcuate nucleus, where these cells we're talking about live, is at the base of the hypothalamus. So it really is like, you know, dipping, dipping a sensor into a stew, and sort of detecting the the full soup of what's in there. Yeah. Yeah, exactly, interesting. So let's give let's give people a sense for how dramatic some of these effects are. So you said that you have these AgRP neurons, and they are basically, they're opposing the action of palm C neurons, and they are or exogenic. So, so they promote feeding. What happens if you take a mouse that's got a full tummy, it just ate a full meal. And you turn on these AgRP neurons, they immediately,
Giles Yeoand that's, that's the thing. So, so like, if you do it, like using optogenetics, so something very, very quick, all right, you can do it using optogenetics, which is quick. You can do it doing chemo genetics, which is like dreads and stuff, and they'll take a little bit longer. But ultimately, when you activate AgRP, when you inject a GRP, but when you activate AgRP, the mouse starts eating no matter how full they are. Yeah.
Nick JikomesAnd the famous, to give people a sense here for how strong this effect is, you know, the one of the kind of stats or observations you often hear is, take a fully, fully fed mouse at the end of its night, when they're normally eating. So they're they're nocturnal. This is, you know, their tummy is full. This is when they would normally eat the least amount they're going to eat all day. If you turn on these neurons by one means or another, they will eat, oftentimes, as if they've been starved for 24 hours straight, which, for a mouse is, is very, very hungry. It
Giles Yeois very, very hungry. It is really quite it's really quite dramatic. Just Just one comment to make on the dynamics of pump C and AgRP, the differences. So unsurprisingly, when you take a mouse or a human being, for that matter, but easier in a mouse, obviously, and you fast them. So in other words, you nutritionally perturb them. What happens is AgRP is very volatile. Okay, so, in other words, levels of AgRP, mRNA, at any rate, if you fast, the mouse will go up eight to 10 fold in an overnight fast, for example, pump C, however, for whatever reason, okay, is far less volatile, far less dynamic. It probably changes two fold, maybe three fold in a fasting feeding type situation, as opposed to AgRP. So of the two pairs, HRP is definitely the more volatile of the of the siblings, shall we say.
Nick JikomesAnd then what can you tell us about, sort of, the one of the next nodes in some of the circuitry you said, both of these cell types converge on the melanocortin receptor we talked about. You mentioned a place called the PVH. This is just another part, sort of the next part, in a sense, of the hypothalamus. What, you know, so, so the arc, so this nucleo hypothalamus, where the palm seed neurons and the AgRP neurons live. It's, you know, dipping. It's a sensor dipped into the stew of the bloodstream. It's sensing leptin. It's sensing other nutrient content in the bloodstream. And then there's some net signal that gets sent out some amount and pattern of activity from the palm c part of it, some amount from the AgRP or go eat part of it. And these signals are converging on melanocortin neurons elsewhere. What is sort of the next step in the circuit? What's happening there? I
Giles Yeothink the melancholy neurons are probably the first of the effector neurons, okay? So they're one step away from the sensor, which you can I mean, it's pumps in other neurons that are sensors. And then, obviously they then begin to something has to happen, right? Eventually, it's got to get to our eyes, our nose, my hand has got to reach a spoon and dip it into the ice cream bowl and put it in my mouth. So I think the MC four receptor as the first of these effector neurons. And so they then sense either the balance between pump C and HRP, and then begin to begin to influence feeding behavior. So
Nick Jikomesroughly speaking, we can think of the arcuate and the palm seen the AgRP neurons as sensors of, you know, fat content, nutrient content in the blood, etc, and the sort of net or integrated signal from them that converges on melanocortin neurons at the next node that signals basically saying, this is our need to feed. And then that's going to then be broadcast to other systems in the brain, ultimately, that are going to tell us to pay attention to certain things with our eyeballs or move our body in a certain way, et cetera, et cetera. Correct?
Giles YeoBecause now the policy is an AgRP built to only express in the arcuate nucleus of hypothalamus, policy in the hindbrain as well. But we'll ignore that for a second. It is only there. And there are very few of them in the mouse, they're probably only 3000 POM C neurons and an equivalent number of AgRP neurons, like literally, all right, in humans, there's probably 10s of 1000s of them, but we have hundreds of billions of neurons in our brain. So these are very, very few the moment you get to the MC four receptor as a secondary, second order neuron, shall we say, effector. There are far more of those. And the MC four receptor I mentioned the periventricular hypothalamus and but it's actually present in a wider spectrum of neurons within the brain. They're far more MC four receptors than they are pump C neurons.
Nick JikomesSo these are fair to say, that. So these neurons are, they're tiny in number in the context of of the full brain, and they're pretty dedicated. It's fair to say, probably that they're, they're specialized for a particular type of of signal.
Giles YeoThey are, they are. So from the broadly speaking, they're specialized for homeostasis, energy homeostasis. I mean, it does a number of different things as well, in terms of glucose and stuff, but broadly speaking, it is specialized. They're nutrient specialists.
Nick JikomesAnd are these neurons? I mean, are they just like, are they just affecting feeding behavior and hunger? Are they other? Are they also affecting, is there activity affecting other aspects of metabolism, like your basal metabolic rate and things like this.
Giles YeoSo now that that's interesting from the mouse perspective, there is evidence that perturbation of the electromagnets pathway has changes in terms of metabolism, either at basal level or reactively in terms of for other things you might be doing, say, changing your diet to a high fat diet, or something like that. Humans, however, with these same mutations and hence have also severe obesity, there has been no evidence to date of any significant changes in metabolism when it comes to mutations within the same pathway. The question comes down to why? I don't know. I think, I think there is going to be a size issue where mice are clearly far, far, far, far tinier. And so I just get the feeling their metabolism is very, very, very twitchy. Human beings are large, lumbering creatures. Maybe there's an issue where it's very difficult to finally measure metabolism in humans, but these studies have been done in these big chamber calorimeters. They've been done pretty, pretty well. So it's interesting. So there are changes in metabolism at the in rodents, in humans, far less so in humans, the only genes so far that have shown significant changes in metabolism are changes in a thyroid, in the thyroid hormone system, but with regards to the left in the Nano COVID pathway, severe obesity, yes, okay, eating a lot, yes, metabolism, no, okay.
Nick JikomesGot it? Okay? Interesting. So let's go back. So now, now we sort of have some sense of certain parts of the hypothalamus. We've got the circumventtricular organ, the hypothalamus itself, and the arcuate nucleus in particular. It can sample from the bloodstream. It can detect leptin and other things. You've got your palm C, anorexic, anorexigenic neurons. You've got your HRP or exogenic neurons. They've got, you know, it's your pedal and your break with respect to feeding behavior, they send signals downstream. We talked about this OB, O, B, mouse at the beginning that was severely, comically obese because it's got a mutation in leptin. So its brain is basically fooled into thinking it's got no body fat because it can't detect that body fat signal that's circulating in the blood, and therefore the animals are hyperphasic. They're eating a lot, a lot, a lot. Have we observed that mutation, the equivalent mutation in humans, and does it have the same result? Yeah. So there are
Giles Yeomutations in leptin and the leptin receptor. We'll start with those two in humans as well. And they are, in effect, phenocopies. The only phenotype that doesn't, that doesn't come out, is the metabolism thing, which, which I talked about, everything else is true. So obviously they have either hyperphagic, hyper for more phagic for eat, and it's a pathogenic term, okay? So in other words, they have this really voracious appetite because they think they're starving. Okay? They have a brain that thinks they're starving. Um, they are infertile. Or at least they have something humans have something called hyper the hypogonadotropic hypogonadism, so So infertile, they don't go into puberty. They also have an impaired T cell mediated immunity, a bit odd to be talking about within a obesity setting. But actually, these last two phenotypes, together with the starvation, together with the fact that leptin reflects fat mass, begins to give us an idea of the biology of leptin and and the reason there is infertility and a weird immune system is because when you are starving, a number of things have to happen. A number of things happen. Okay, when you're starving, you obviously have to eat, yes, and when you're starving, you eat foods that you that you don't eat poison that will kill you, but you eat foods that you may not find palatable.
Nick JikomesSo these kids, you'll be less discriminating in what you choose. Yeah, you're not discriminated.
Giles YeoSo these kids, for example, have to have freezer, have to have locks on their freezers, because they'll go in and eat frozen food. Yeah? So it's a clearly, it's a pathology, but it's not poisonous. It's just unpalatable. If we're not starving, right, right? If you're starving, you're doing so from an
Nick Jikomesevolutionary perspective, the basic idea here is, if your brain truly thinks it's starving, and you don't have any fat, because you can't sense this Leptin hormone, you will from an evolution. Sharing perspective, right? It's all about getting your lineage to persist, which means you've got to reproduce, which means you've got to survive long enough in order to reproduce. And so if you are about to starve, obviously that's not going to happen. And so the body de prioritizes a fertility related things and B, fighting off infections so that it can sort of essentially allocate resources to not immediately dying through starvation. Is that the basic idea?
Giles YeoIt's doing triage. Yeah. So, so your brain says, All right, guys, you know, we just have to triage this and begin to triage calories for our brain, and like, specifically glucose your brain, for those of you who don't, who who just dig back into basic biochemistry, um, your brain doesn't use fat, okay, your brain uses glucose and some ketones at moments of stress, but your brain doesn't use fat. So as a result, you really have to maintain your glucose levels above a certain level for your brain to function. And so it begins to triage all kinds of things to ensure that the command and control center of the brain continues receiving glucose.
Nick JikomesSo we have comparable mutations in the leptin gene in humans that we see in this OB, O, B mouse, they have, you said it phenocopies. So they are very obese. And you know, you just described how they have this voracious, pathological hunger. I'm guessing this is a very rare mutation, yeah,
Giles Yeoso in humans. So it was first i So the people who identified the first leptin mutations were my, I mean, he just retired as head of department, but my head of department for a long time, Steven rattly and his at the time clinical fellows, tada Fauci and they identified the first kids with leptin deficiency in 1997 now, since 1997 there have probably only been a less than 100 families worldwide with with mutations within leptin, further up the pathway. Is very different, but within leptin and maybe an equal number of patients with leptin receptor mutations so roughly, so incredibly rare, by no means a common cause of obesity.
Nick JikomesSo the discovery of this mutation, you know, it was a significant mutation, because it led to all this sort of path of discovery that we've started to discuss a little bit. But certainly this one mutation isn't going to explain something like the obesity epidemic that humans are experiencing, because most obese people don't have this particular mutation, I want to ask you now a little bit more about genetics as it relates to obesity and adiposity. What? What can you start to tell us about the genetics there and other mutations and other genes that we think are linked to one's propensity toward obesity and and high fat deposition. They might not be as dramatic as this leptin receptor mutation, but are there other genes or a strong genetic component here that we should know about?
Giles YeoSo the VA So there, I mean, I guess you could almost think about it in two different ways. There are very extreme cases of obesity, and there's more subtle changes, like normal distribution of body weight. Sticking with the extreme obesity cases, they eventually overlap. But speaking about the extreme obesity obesity cases, the vast majority of of single gene, or at least very, very strong genetic drivers for for obesity, lie within this leptin melanocortin pathway, throughout the entire pathway, all right, mutations and all the genes results in severe result and severe obesity. There are other genes to be found and have been identified, but in total, if you actually add those up that are not part of the leptin millennial codes and pathway, they are tiny, Itsy, Bitsy, teeny weeny things and and what they do is they give us site insights into certain other biology, but the primary genetic driver for it is variation within the leptin
Nick Jikomesmelanocortin so, so if you, if you sort of break or disturb a number of different levels of function in this leptin melanocortin pathway, you can get severe obesity phenotypes. It's, you know, what you're basically saying is this leptin land, a court pathway is sort of like the, this is the important piece. It's not that there's nothing else going on elsewhere, but that this is a key node, and you can break it in multiple different ways.
Giles YeoSo there's interesting, actually, there's two ways of viewing it. It's sort of, remember the, you know, the memes which go about, which show you the picture of the airplane being shot up in World War Two, you know, yes, yes. And what they and what they show. So there is a survivor bias, okay, so I think it's definitely a pathway that is tunable and tweakable, and therefore is very important. I just get the feeling it's probably the reason we see so many mutations is because it's a pathway that can take a lot of hits and and it's a tunable system. I get the feeling that the actual, truly existential pathways, if mutated, we're dead. And so hence we don't see mutations in those very frequently I see because they probably do not have any redundancy in those particular pathways, or at least are not designed as a rear step, that they're not designed to be tuned. And so if you knock them out, you. That's it. So, so the importance, it's interesting, is an interesting discussion, probably too niche for people, but, but I don't know if it's the most important pathway. It's certainly the most
Nick Jikomesit's very tuneable pathway I see, I see, okay, and so I want to ask you a little bit more about genetics before we circle back to neurobiology. Um, so there's this sort of just general question in in society. So obviously we've got this obesity epidemic. Everybody's got a different opinion about exactly how we explain that and what to do about it on the genetic side. So obviously, there's not a bunch of people walking around with OB, O, B mutations in the leptin gene. It's not like in, you know, 1940 there was a mutation in the leptin receptor, and it somehow spread, and that explains the obesity epidemic. But I want to sort of ask you how much of the variation we see in body weight and obesity can be attributed to genetic factors. And we'll probably have to spend a little bit time here really unpacking that for people, because it can be confusing to think about, but I'm just gonna start there at a very basic level. How do we start to think about how much of the variation in obesity is attributable to our genes, as opposed to our environment?
Giles YeoSo we do have a number for that, actually, and that's because, that's because of studies from twins. Okay, I actually you can do the same thing for any given human trait or behavior, but and you, and a lot of it has come from twins twin studies. So So you have clearly monozygotic twins, identical twins, who are, for all intents and purposes, genetic clones of each other. And then you have dizygotic twins, so non identical twins, and they would share as much genetic material as you would with your own siblings or your parents, so 50% and so if you study a large enough cohort of twins, 10s of 1000s of pairs of twins, identical and non identical, then you can ask a question about any given human trait or behavior, what happens when you share 100% of genetic material versus 50% and from there, You can then come up with a measure called heritability, which is what you just asked, the variation in a given trait that is down to genes versus non genes, which we can say, environment, okay? And if you do that, do that math, what you end up with is the heritability of fat mass, body weight, okay, is between 40 to 70% so it's a pretty big range. It's a pretty big range, but, but broadly speaking, that is, that is the amount that is attributable to genetic factors. And
Nick Jikomesso let's, let's really unpack that for people who are unfamiliar with this stuff. So you said 40 to 70% let's just, let's just, I'm going to use 50% a number kind of in the middle of that range. Does that mean that 50% of the fat on someone's body is due to their genetics? Only?
Giles YeoNo so heritability is a population level measure. So what you gotta do is you gotta look at 10s of 1000s, hundreds of 1000s, millions of people, and say that at the population level, you have variation in given traits, and of that, it is likely that 50% on average, is down to your genetics versus the versus the environment as an individual. Clearly, your body weight is what your body weight is and it you're then asking a different question. You're asking a different question about about the role that genes play within an individual, but heritability is a population level measure, yeah,
Nick Jikomesyeah. So yeah. So we're talking about, yeah, the variation between people in a population. This can be a little subtle for people, but can you give us a sense here for what the variation in like BMI is, or obesity, if we, if we were to take random people from the population, you know, how variable is it? Actually, it's
Giles Yeovery variable, because obviously you go from from, so actually the the distribution is one of a tail, okay, so you have, you sort of have a, it's not a normal distribution, per se. It's like a distribution with a long tail. And the long tail is where the body weight is, okay, because you got, you got people who are, most of us are average body weight. Okay, a little bit heavier than we like. And then as we get out to the tails of severe, severe, severe obesity, then there are fewer and fewer individuals. But it's sort of like a normal distribution with a very long tail on the on the right hand on the right hand side. But the variation is enormous, because we can go around and we can see that they're really super uber thin people for many different reasons, okay, but Uber, super thin people, and then you have the rare cases of severe, severe obesity in which people need to, you know, get holes cut out of their roof and craned out of their house, you know, like, like, really severe, severe type of obesity. But most of us clearly sit within a normal, a normal range, even though this range is increasing as we speak.
Nick JikomesYeah, so, so depending, depending on how you count, yeah. I mean, there's, there's no start date for the obesity epidemic, but you know, in the mid 20th century, let's say 1950 Give or take. Obviously, obesity rates were very different. So the absolute number of obese people was smaller than than it is today, and the distribution of fat phenotypes was yes, was narrower. How do how do population level changes in rates of obesity like that, both the average level and the the distribution. Does that affect our estimates of heritability at all over time? If you were to estimate the heritability back in 1950 versus today, would it be affected by those changes?
Giles YeoNo, because the heritability is not of is not of obesity, it's the heritability of body weight and so hence, yeah, okay, the dynamic range may be slightly narrower, so so maybe you need a larger number of twins, for example, in order, in order to actually identify the heritability. But the heritability is the heritability, right? And so you're just looking at body weight, size, and in with enough twin, with enough pairs of twins and enough people, then you you can actually, you can actually see that. So it just narrows the dynamic range slightly. It's not going to change the heritability. What will change, heritability. However, interestingly enough, is the environment. Because heritability is a, is a it's not you can't just study genes in isolation, because your genes are not there to function in isolation. Your genes are there to allow you to adapt to the environment. And so if the environment changes, it can change the heritability of your of what happens so this 40 to 70% why this huge, gigantic range? Why didn't I say 50% Why didn't I take an average? Because the environment really influences the level of heritability. That's something I
Nick Jikomeswant to emphasize for people, because this can trip people up. You know, there's this inextricable link between genes and environment, like you. Again, you just said the environment itself changes. In the environment change the heritability of these things.
Giles YeoSo let me give you one example. All right, because I know, because it blew my mind. Okay, so, so a colleague of mine, Claire Llewellyn, Professor, Claire Llewellyn, who's based down in London at the university, at the University at University College in London, she has a twin cohort, okay? And she is interested in body weight as I am, which is why we're colleagues. Now, the interesting thing is that her set of twins is called the Gemini study. For those of you want to google it, Gemini, her set of twins, she includes all the anthropometric measures that you would assume with there would be there. But she also has interestingly socio economic markers for these twins, okay, so, so within, within society. Now, if you go, or if she went to the twins with the in our households, okay, sort of a academic, professional class individual, not someone who's rich, you know, just just, we don't have to worry about our food, right? We know where we are. Type of situation, middle class. But in the UK terms, the inheritability of body weight was around the 40% mark. Okay? Now, when you went to the households with the poorest food environment to the lowest socioeconomic status. Suddenly, heritability maxed out at 70% I read the study, I was going, Dude, what is going on? And this is the way that I rationalize this particular concept, all right? Now, imagine so I look, I accept, I'm a privileged human being, right? I'm a professor Cambridge. You know, I live in a nice leafy Village. Now, my nice leafy village here, Deliveroo is so far away from anything. Deliveroo doesn't deliver out here, okay? And we don't have any takeout in our in our village. So imagine me, and I have a high genetic drive to eat, just as an example. Now, if I were hungry tonight, for example, I can't just wander down. I can't call the liveroo. I have to look at my fridge or get in my car and drive to the supermarket and do something about it. Okay, but if I look at my fridge, maybe I'll find carrots. Maybe I'll find some homeless. Now, imagine there's a me in terms of the same genetic drive to eat, but I'm now in town, okay? I'm now in a inner city location, I live above a takeout i I'm in an area, maybe a food deserty type place deliver. Definitely delivers, all right, and suddenly my ability to fulfill that drive is far, far, far easier. Okay, I'm getting in my car. I'll wait till tomorrow, like, really, I can't be bothered, whereas if I can run down the stairs or call Deliveroo and eat it, I probably would. And so that's the difference, right? I'm privileged. I live in a leafy green place, whereas if I was less privileged and lived in not a leafy green green place, but had the exact same genetic drive to eat, then I would be able to respond to those signals better you
Nick Jikomeswhat I mean? Yes, yes. Essentially, the extent to which you've got a genetically driven propensity to hunger, whether or not that can lead to an outcome of overeating, is going to depend on the availability of the food in your immediate environment. So the type of food. Food, yeah, and the type of food, like, even at an individual level, this is, this is actually, like, kind of how I regulate myself in my home. I know that what I eat and how much I eat is going to be tied to what I have in the cupboard. And so I I make myself not have full cupboards most of the time, because I know that if it is full, I'm gonna eat way more just because I can
Giles Yeoexactly and and that's just a situation. And then then there's a whole complexity of what you have in your cupboard. Those tend to be more processed foods because they are in your cupboard rather than in the fridge, you know, and therefore longer shelf lives and so, and they tend to be cheaper than fresh food, right? So you now then go down the rabbit warren of the fact that, well, okay, so not only is socioeconomic status linked to where you live and what you can access, then to what type of foods you have. Are you leading fresh food? Are you eating food that is, that is pre processed, you know? And then you can get into a deep discussion about socioeconomic class and health and body weight.
Nick JikomesOkay, so, so I want to talk about glucagon like peptide one, so you mentioned it briefly earlier. I want to talk about what that does, sort of normally, and then we'll talk about the new weight loss drugs. So what is glucagon like peptide one, and how does it work and tie into some of the circuitry and stuff that we were talking about earlier. Okay, so
Giles Yeoglucagon like peptide one or GLP one, otherwise, we'll be here all day. Okay, is what we call and it's a, first of all, it's a gut hormone. So it's one of the hormones that go up. We know of 20 different gut hormones, so GLP one is one of them. It is called an incretin hormone. Now there are two incretin hormones, GLP, one and gyp, which I'll get back to in a second. Now they're called, What are incretin hormones? I guess. Let's deal with that first. So when you inject yourself with glucose sugar, your insulin levels go up. We understand the biology, obviously, but when you eat glucose and so hence has to go through the stomach and then passes through the gut wall. The act of eating, it enhances the insulin secretion by eight to 10 fold. Okay, exactly the same amount, amount of glucose. Now this effect is called the incretin effect, and the reason it happens is because as glucose passes through the gut wall, GLP one and Jip in particular, go up, okay, and they signal to the pancreas and enhance insulin secretion. So GLP one and gyp are incretins because they enhance insulin secretion when you eat sugar, as opposed to inject sugar first.
Nick JikomesSorry. So because, because we're animals that evolved and, you know, we eat through our mouth and swallow it, that's the way things are supposed to go. If you were to inject glucose in your bloodstream, which, you know that happens sometimes in experimental or clinical context, you're basically bypassing some of the natural satiety and feeding signals that have been evolved into the body, and your body won't think you've eaten as much as actually you've injected Exactly,
Giles Yeoexactly. And so that's the first thing they have an increase in effect right now. Park that. Now gut hormones, of the 20 of them, for example, most of them make you feel full. Of the eight of the 20 gut hormones we know about, 18 of them make you feel full. Only two make you feel hungry, right? So in totem, as we eat as food, kind of shuffles through, through the food to poop tube, shall we say? Okay, all these hormones are released, including GLP one and Jip and so when they signal to the brain, they tend to make you feel fuller. Okay. So now that two things, right? So GLP one and Jep both enhances incidence secretion and make you feel fuller. Okay? Now, then we begin. So that's, it's not it is it's, it's natural, native hormone, and it's physiological role. And the new drugs are all at the moment modified. They're called inquisit based treatments. Some of them are only GLP one. Many of them are now GLP one and gyp as well. But they're called incretin based hormones, because the vast majority of these new class of drugs that everyone is talking about are modified versions of these two inquisit hormones. So GLP
Nick Jikomesone, it sounds like there must be a lot of GLP one sensors in the pancreas. But I imagine there's also some on these neurons in the parts of the hypothalamus. We talked about,
Giles Yeoyeah, so the GLP, I mean, there was a debate at the moment, to be fair, about the balance between hypothalamic and hindbrain sensors for GLP one, okay, and what the balance is, and I think it will all come out of wash. There are people who says it's all high brain. There are other people that says that the hypothalamus plays a bigger role, but undoubtedly there are receptors within the hypothalamus and within the hindbrain for these Inquisition receptors. And
Nick Jikomesso how does the synthetic GLP one weight? Drug differ from endogenous GLP one in terms of how it acts, where it acts, and how long it
Giles Yeolasts. Let's start with how long it lasts, because that's its primary difference the native incretin hormones, GLP one and gyp have very short half lives. GLP one, for example, only has a half life of a couple of minutes, two minutes, it's then chopped up by an enzyme called DPP, okay, DPP four in particular, which chops up. GLP one. It's designed to be very volatile, okay. It goes up quickly after a meal, or when you're eating, it then disappears and it comes up again. The these. So the class of drugs, these increasing class of drugs, have actually been around a long time, a couple of decades, but for the longest time, it was only a one's daily injection. So in other words, they through molecular decoration, shall we say, of these specific of these specific hormones, they kept it around the blood long enough that you only that you could inject yourself once daily. The Big Leap came with semaglutide, for the those of you don't know, is ozepic, okay? And we go, V whatever reason and how they decorated it, you know, you get after companies. Um, these were then once weekly injections. So that's the first thing. The superpower of these new of the of these new drugs, primarily, is their half life, because they stick around the blood for longer, and once weekly is more palatable than what and then injecting yourself once daily. Now it's a more complex question to answer than you might imagine, about where what else happens? Okay, but let's, let me try my best to do to do so peripherally, so, when I mean peripherally, I mean south of the neck, I think these drugs hit all of the same organs as the native hormone does, broadly speaking, the part of the north of the neck. However, very, very, very little of the native hormone actually probably makes it up to the brain. Okay, so the complexity is, well, what the hell are the receptors doing there? Well, as it turns out, there are brain specific, what we call PPG neurons, pro glucagon neurons. So they are the source peptide for GLP one. They are a small population of glucagon neurons within your brain, and so GLP, one within the brain is clearly doing some physiological thing. Which would you believe? We don't actually know what that actually happens in a local brain circuit that is actually there. Okay, it just so happens that because some of these receptors sit and they probably sense Femto, I don't know what molar, but sense very, very low levels of it, very, very small amounts. But the pharmaceuticals that are based on these hormones are hijacking the system to make us feel fuller. So just recap, recap, okay. Peripherally, I think that the these new drugs are hitting where the native hormones tend to be, tend to be hitting. Okay, primarily the pancreas.
Nick JikomesBasically, what you've said is, so the weight loss, vert drugs, the these, these synthetic versions of GLP one, they're engineered to have a longer half life due to the normal time, of course, in half life of endogenous, natural GLP one, it's hitting a lot of targets in the periphery, such as the pancreas. After we eat something, and it gets down to our gut. But there's probably not much of it that actually makes it up to the brain to stimulate the neurons that are sensitive, that are nonetheless sensitive to GLP one. But because the drugs are engineered by humans to have a longer half life, they are stimulating GLP one sensitive neurons in the brain way, way more than native GLP one would
Giles Yeoexactly, and that's how they work. So therefore they make you feel fuller. So they're designed to sort of sense all 20 different gut hormones and have a balance of well, not only how much have you eaten, but what you've eaten as well, how much protein, how much fat, how much carbs. But suddenly, when you then change significantly the concentration of one of these hormones, or two of these hormones, or two of these hormones, depending on which drug we're talking about, suddenly you're going, I'm full, and that is, in effect, the mechanism for the weight loss. Because you're full, you eat less. You eat less, you lose weight.
Nick JikomesInteresting, and what's your sort of general take on these drugs in terms of their effectiveness, their effectiveness for their their primary, you know, marketed use and what we should look out for or be mindful of as the months and years go by, in terms of chronic or long term effects they might have that we currently don't realize or appreciate. Great
Giles Yeoso well. First of all, I've been in this business for 30 years, and we have never had these many effective tools before. And, you know, yes, there's semaglutide, ozempic slash, mugovi monjaro, which is tour zepat. Effect size is anywhere from 15 to 25% I mean, there's this a weight loss over a couple of years. Incredible. We. Ever would have thought this possible five years ago, but here we are, okay. So they're very effective. Okay, extremely effective. They're broadly safe, at least when it comes to it's the common side effects. And the common side effects, because these are gut hormones tend to affect the gastrointestinal tract, okay? So some people may feel a bit pukey. So this side, some people may have the the problem of too fast or too slow in a gastrointestinal tract. So diarrhea or constipation, those are the three big side effects that are picked up by all the trials. It's it affects a small minority of people, rather than it being affecting everybody, but it does, but, but that does happen. So, so we do need to watch it. Well, it's most of the people that start the trials finish the trials, so it's can't be all that bad. Now, what you you're right in saying is that as more and more millions get these drugs, now we're going to identify rare and super rare side effects. The side effects can be positive or negative, incidentally, and
Nick Jikomesto preempt you a little bit here the trials that have been done, can you give us a sense for about how long those trials tend to last. So,
Giles Yeoso in a in terms of, in terms of trials, all of these trials have been two years. So they tend to took two years. So they, first of all, they have phase one, phase two, phase three. But the phase the big phase three trials are all two year trials, and they will all completed it because no one started dying or anything of that sort. So the safety data for these ones weekly, the ones daily injections, have been around a couple of decades. So from first principles, they are safe, okay? Within that context, the problem is, when you change from once daily to a once weekly, you change the kinetic profile, right? You so that was different amounts of your so we need so we know they're safe for two years. What we need to know now is that they're safe for 20 years, 30 years, 40 years. And the only way we're going to know this is time, and the
Nick Jikomestrials that have been done have those primarily been in adults, like adult adults. And do you think there's anything we're thinking about here? If you know there's definitely a push to give these drugs, not only to young adults, but even younger people. Do you think there's anything we should look out for here when we start to think about giving what is essentially a hormone therapy to people who are not fully developed, to put to broadly speaking, yeah,
Giles YeoI mean, it's a, it is a really Pandora's box you're trying to think about here. So now, obviously the all of the primary phase three as these drug companies do tend to focus on adults with the disease, in question, obesity or type two diabetes. It has been trialed down to adolescents, but definitely post pubertal. Okay, post pubertal, adolescence, and it works effectively in it. I just get the feeling that for anyone younger than that, it's very tricky, right? It's very difficult to trial these things in children unless they're so, for example, leptin deficiency, you can be given leptin, but that's because the risks of not getting the leptin to treat the super rare cases of leptin deficiency far outweigh any risks that you're going to get from giving the leptin the leptin treatment. Okay, and plus. So there is that for something like GLP one. Do I see it happening in kids? Maybe, but I just feel that in children, particularly children preview Bert, there are many more levers that we can that we can actually use. We can more easily control the diets of children than we can the moment you get an allowance and you can go spend money on food, then you get screwed that we need to think about other things. But I think for kids, people, understandably, will always be far more careful, particularly when there are other levers to use in order to affect their diet and therefore their
Nick Jikomeshealth. You know, these are kind of purposely vague questions I'm going to ask you, but you know, given your background, you know, I would love your general take on. So obviously, we can tweet. We can we can mess with gut hormones and satiety systems, and it seems to have real effects on how much people actually eat, and then obviously we've got this obesity and metabolic health epidemic that we're dealing with. So at a high level, What's your general take on why people can't better regulate their energy intake and their food habits unaided. What is, what is actually driving all of the overeating and obesity from your perspective? And I understand there's probably, you know, you're not going to have the answer, but you probably do have some perspective on this.
Giles YeoI have an answer. It's not, it's not the only answer. So, so if we look at. So we know of over 1000 genes, 1000 loci, to be fair. But anyway, we know of over 1000 genes that play some role in influencing our feeding behavior and hence our body weight. Right now, they sit in multiple different pathways and do multiple different things, but I'll so I'll just give you two examples. Okay, so for your brain needs to know, I think we've wave, I've just, I'm repeating myself here, but your brain needs to know long and short term energy stores right in order to influence your food intake. And some of these genes sit within the pathways that sense these long and short term energy signals. And put simply, and I'm being slightly facetious here, particularly if you're experts in your in the listeners out there. But in effect, because these brains are less because these some people have brains that are less sensitive to leptin, less sensitive to GLP, one less sensitive to any of these signals, they are likely to underestimate how much they have actually eaten or how much fat that they're carrying, and therefore make them eat more. So in very in simple terms, it's like a thermostat, okay? And I think there are many other pathways, but ultimately what happens is, what these genes do in totem is change your drive towards food. This could be reward pathways, hunger, fullness, the full gamish, all right, but some people are going to be more driven towards food than others, and so given the environment that we're living in, okay, if when you go put gas, when you go buy a Tylenol from the from from the drugstore, and suddenly there's a chocolate bar in front of you, some of us will send and Wonder, buy the chocolate. But other people go, ooh, chocolate, and eat the chocolate. Okay? Like you're saying that if there's food in your closet, not closet, if your food in your cupboard, then you're more likely to eat it. Then if it's not there, same, same for me, right? And so that is that tunability, the gene set that drive for food. And there are multiple mechanisms, and it's complex, but ultimately it sets the drive for food, where some people find it more difficult to say no than others, that is what is happening. So the more difficult you find this, the more aid you're going to need to lose weight. And this is where the drugs come in. Okay? Because some of them, some of us, can do it through behavioral therapy or group support, like Weight Watchers or what have you, other people will need drugs in order to help you turn down that dial
Nick Jikomesto what extent so. So when we think about things like just the raw number of calories you eat and whether you're whether or not you're in positive energy balance versus what you're eating and metabolic disruption and things like this. To what extent do you think obesity patterns are just due to positive versus negative energy balance, and the total number of calories versus the specific types of foods and things that people are consuming? Is obesity merely about energy balance.
Giles YeoI mean, in one level, it is clearly physics, so it has to be about energy balance. The complexity lies in not the how, which is physics, but in the why and so and so. Ultimately, the the output of obesity is a energy imbalance, one way or the other. Right, in terms of obesity or being or being underweight or being average, the complexity lies in the driver. So the complexity lies in the why somebody eats more or eats less, primarily, you might ask, Well, what about the other side of the energy balance equation, the metabolism? What's interesting is, when we look at these 1000 genes that influence body weight, they all influence food intake, and they all, vast majority, sit in the brain. We have not identified at the population level genes that have to do with your metabolism, which is interesting, because twin studies have shown that they definitely are genes to do with your metabolism. Some people are more efficient than others, right? So why haven't we identified them in these big genetic screens? So I think there are two reasons. I think the first is a measurement error, and the second is effect size. So let's just break that down so it's easier to it's not easy, but it's easier to measure food and take because it's a physical measurement, right? Here's a slice of pizza, here's a can of Coke. You can we can weigh it. You can look at the volume. The problem with metabolism is there are only two real ways of measuring it, and not even at scale. Okay, you have to either measure heat or you have to measure your CO 2202, ratio that you actually breathe in and breathe out. So that is possible to do, but very difficult to do at scale. So there's a measurement error, number two, effect size. Now a normal size snake asy marzy type chocolate bar is probably, what a couple 100 calories, two to 300 calories, right? And if I'm motivated, I can probably snaffle down a Mars bar in 30 seconds. But it doesn't matter. How fast or slowly I eat the Mars bar, I'll still need to spend 20 minutes on a treadmill or something to burn it off. Okay, so we're designed to eat food a lot quicker than we are to burn it. From an evolutionary perspective, this is what has kept us alive. We're very efficient creatures. So if you look at that, then it is the effect size of metabolism is just far, far, far, far, far smaller than the food intake. It doesn't mean that the genes aren't there. It just means it's more difficult to
Nick Jikomesidentify the genes there's there's plenty of genes that affect metabolism and and we know what some of them are, but those, what you're saying is those. Those aren't the ones that seem to correlate or map to variation in food intake and obesity. Correct? When you are thinking about your so what like just to the extent that you want to tell us, how has all of your knowledge that you've accumulated and the field that you're in, how has it affected how you think about your own relationship to food? Do you think primarily just in terms of the number of calories you're consuming, or do you pay a lot of attention to the specific types of calories and things like that?
Giles YeoI think more and more, and I've reflected a lot on this, actually, in terms of the calorie, and we talk about calories, but they're a unit of their unit of energy. And as society, I think we're obsessed with calories. It's sort of an easy number to think about. It's a people think it's a composite number that reflects the health of your food, how healthy your food is. But it isn't right. What calories are, what are they? They're a very one dimensional figure. They tell you. What it tells you is how much food you're eating. And that's fine. That's important. It's important. So 200 calories of potato chips is twice the amount of potato chips. That's 100 calories of potato chips. Potato chips, or for example, but so is 200 grams of carrots, twice the amount of carrots, that's 100 grams of carrots. And no one is trying to compare 100 grams of carrots to 100 grams of potato chips. So calories give you the amount of food, it doesn't give you anything about the nutrients, the nutritional density of the food, nothing, fat, salt, sugar, fiber, nothing. So calories, we need to focus on the nutritional density of food rather than the calories. I mean, for some people need to eat less, I grant you that, but I think a bigger problem we have is nutritional density of food rather than necessarily too much calories.
Nick JikomesOne thing I want to circle back to, that I intended to get to earlier is leptin resistance. So so we started off, and we spent some time in this discussion talking about the the famous OB, O, B mouse, and these rare, rare, rare mutations where the body can't sense its fat levels because something's wrong with a leptin um, most people don't have that mutation. Most people can have a sort of intact leptin system when they're born. There's nothing genetically defective about it, and yet leptin resistance can and often does develop in people. Can you talk a little bit about what leptin resistance is and what we know about how it develops over the course of the lifetime? So leptin
Giles Yeoresistance is an interesting term because it's a controversial term. So I, for one, think that it's a misnomer. Okay, so, so first of all, where does this leptin resistance thing comes from? Or what is it? Okay, so the whole because leptin reflects fat mass, the more fat you have, the more leptin you have. But when you take leptin and you inject it into a mouse. Now it's different in humans, but when you inject it into a mouse, a mouse will lose weight. Okay, so, so leptin is anorexogenic, because it signals to pump C and you end up eating lot less. But where the leptin resistance comes from? But wait a minute, but if you but the fatter you are, the more fat you have, and the more fat you have, the more leptin you have. Why is the leptin not signaling to the brain to let you know that you have now too much fat? Please start eating less. That is the leptin resistance. I don't I think it's a misnomer. And I think it's a misnomer because it's a pharmacology question rather than a biological question.
Nick JikomesSo so the raw, the raw observation is there's lots of people out there with high levels of fat and therefore high circulating leptin, but their body doesn't seem to be responding to that in the way you would expect. But I think what you're about to tell us is that may not be resistance at the level of like what a pharmacologist would say exactly,
Giles Yeoexactly. I think it's where the the if you have pharmacology, for those of you remember your basic pharmacology, you have a curve, right? And you obviously have, where is your where does the curve meet? That sort of the maximum effect size, and where do you actually saturate the system and have no longer an effect? I think leptin is designed to function very, at very, very low concentrations, because it's designed to turn on the starvation response. It's designed to tell you you don't have enough leptin, and so when there's loads of it around, which means that you actually have enough fat, your brain does. Says there's enough. It doesn't matter whether or not you have two kilos of fat, 20 kilos of fat, or 200 kilos of
Nick Jikomesfat involved to sense that because that much fat was never really an issue,
Giles Yeoexactly. Whereas it is sense, that really tight thing between 200 grams of fat to a kilo of fat, something like that.
Nick JikomesOkay, that makes, that makes a lot of sense, actually, okay. So, so you don't, okay, so it's not, I see what you're saying. It's not. When we talk about resistance, this is not what we would think of as as classic, like drug resistance or something like the like, the receptors have been internalized on purpose because of something, some fine tune effect of having so much of something floating around.
Giles YeoBut that being said, that being said, clearly, if you can find out the mechanisms, okay, that would enhance leptin signaling. Could, could you, for example, improve the sensitivity or change that within your brain so that you could respond to additional leptin, or your brain becomes more responsive to a broader range of leptin? Yeah. And so there are companies out there with drug programs that are trying to do that. They're trying to sensitize your brain to leptin so that it can be used, probably not in isolation, probably together with GLP ones or something else, to actually increase the effect size of some of these of some of these drugs. So while the concept of resistance to my mind, at least, is a pharmacological question rather than anything else, it doesn't mean that it doesn't it doesn't mean that we can't at least learn from it to try and design new therapies. I see, I see,
Nick Jikomeswell, we've discussed a broad range of topics related to the genetics and neuron biology of feeding and hunger and obesity. What are you working on nowadays in your lab related to these topics? What's sort of the exciting what are the exciting what are the exciting questions that are being asked that you think we're going to start to get answers to in the near
Giles Yeofuture? So I mean, there are two things that we still need to understand more about, the genetics. In other words, because ultimately, I think what we are beginning to realize is, as I said, obesity is a simple output of physics, but because each of the drives, each of us have different reasons why we end up eating more, we need to understand more about these because the more of the about this we understand, the better we're going to be at the beginning to tweak the system, and so we're still trying to identify new genes, even though they're super rare. Okay, super rare. Now nothing, nothing that we're finding is particularly common. It gives us new pathways to begin to say, well, are these tweakable pathways or not? Most of them are probably not going to be tweakable, but some of them will be. So that's one thing. So we're working on, still looking at rare genetic causes of severe obesity. That's one but second and the larger, the far larger program I'm working on at the moment now, because feeding circuits are circuits, they tend to be within the brain. The vast majority of our understanding of feeding circuits have come from mice, for obvious reasons. Now, however, and given that we're chucking drugs at the brain for all kinds of things, shouldn't we know what happens in the human context. So now we have access to brain donor samples, and the the techniques have now matured to the point where you can now do single cell and spatial approaches within donor brain samples from archives. So not even like fresh donor brain samples from Frozen samples. That's what we're doing. We're now mapping feeding circuits. We've just, for example, produced a spatial map of the human hypothalamus, the normal weight human hypothalamus. We just published that two months ago, and we're now looking at that in line and obesity, and we're doing the same thing within the hindbrain as well. So So I've become a glorified cartographer. I'm trying to make maps, but within the human context, is there any anything
Nick Jikomeselse you want to say about what we've discussed, or any final thoughts you want to leave? You want to leave people with about the broad topic of obesity and feeding?
Giles YeoNo. I mean, I guess one, one final comment, you know, because we did discuss these drugs for a bit. I mean, something that that people have asked me is, with these drugs, have we solved obesity? Is it almost a panacea? And I'm going to say no, and I'm going to say no for a couple of different reasons, because I think these drugs a not everybody responds to them, but a lot of them do that. They're designed to treat obesity, and I think we do need to do so, but they're not designed to prevent obesity. So prevention of obesity still needs to fix the food environment we live in all right, and that will require policy, legislation and and a bunch of levers that drugs are not designed to pull. The second is, these drugs are powerful, and they will make you eat less, but they won't change what you eat. And so we still need to find ways of improving in our diet as well, in addition to just taking the taking the drug. So I think, just as a takeaway, just in case people think I'm this drug chill, which I'm not, okay. But anyway, I think these drugs are a tool, but it needs to be within the context of broader societal changes, and we still need to eat healthily, even when we're eating less.
Nick JikomesAnd I guess, tell me if you would say. This. But it sounds like you would probably agree with the statement that whether or not you're you're just using your own willpower or using one of these drugs, if you're somehow eating less, you still need to think about what you're eating. Because the only, in my view, the only way the food environment will actually change is if consumer demand changes. So until people start, you know, voting with their dollars and actually eating different things, it's not, you know, the food environments not going to magically fix
Giles Yeoitself. It can be fixed for policy changes if the governments are able to do so. You know what the big problem is? The big problem is that there is always this, this tension between public health and the loss of personal liberties. Okay, we just, we drive on a specific side of the road. We stop when the red light goes red, and we wear seat belts. Okay? So we can't do whatever the hell we want. So, so and reason why it's because it's it keeps us safe. Now, the problem is, is this right? So in other words, for public health purposes, how much liberties are we willing to lose? Now this line is a murky and gray, never politically expedient, but, and it's going to differ between society to society, but and culture to culture, but we need to reach this balance of well, how much personal liberties Am I willing to lose to have a healthier society? And that needs to be accepted by the majority of society, and so, yes, I think that the food environment, that is the only way we're going to tackle it to the loss of certain liberties. I'm not a nanny state person, please, but that's the only way we're going to be able to do this societally.
Nick JikomesHow does that dialog happen? Give so I mean, it's, it's, I can think about this abstractly in the idealized case, but the fact is, we live in a world where, you know, Nestle and Coca Cola and other interests basically control the food supply, almost top to bottom. And like it or not, you know, they are able to integrate themselves into the policy apparatus in a way that circumvents the dialog between the people and the policy apparatus. And so how do you think about that? No,
Giles Yeoand you're absolutely right, and I'm not saying that any of this is a quick fix. So we need, I am, I am one, and I am a believer of engaging with these companies, Nestle, Coca Cola, etc, etc. Okay, some people say we shouldn't talk to them. You know, it's like trying to talk to the cigarette manufacturers. There's a difference between cigarette manufacturers and food manufacturers, and that we don't need cigarettes, but we need food. So I do think we need to engage with the company somehow and get them how would I think about this? I think that we need to try, naively, perhaps we need to try and convince the companies that if they make healthier options, that we will live longer to spend more money with them. So if we make healthy food profitable, and convince the companies this is so, then market forces will make the company actually change that. So in other words, you don't, I think that the bottom up approach, in other words, the consumer voting with their feet, is never going to be this only solution, because the problem is we have chimp brains. And you know, when are we going to vote for for chips in the French fries, you know, against broccoli? You know, just won't do that because of the French fries. Chip brains, all right? And so what we need to do is we need to have companies as well understand from a marketing perspective that, can we make healthy food safety, we probably could, and can we make this profitable? And they probably could as well. And so you're right. It is in no way. Am I saying this is an easy solution, but I'm saying that we at least need to have the discussion.
Nick JikomesYeah, I understand what you're saying conceptually, if you could convince the and it sounds very logical from one view, naive, yeah. I mean, if you can convince the companies, hey, if the population is healthier, they will live longer to spend more dollars with you over their longer lifespan. That works, unless these companies, directly or indirectly, are able to profit literally, from the other side of things, which is chronic disease. So if you're simultaneously profiting from the foods that make people chronically ill and from what they have to do in order to treat their chronic illnesses, then that argument would go away.
Giles YeoYou're a cynic. I sense this.
Nick JikomesI'm not sure I would agree with that, but I'm just but such entanglements do exist, and so I'm just saying your argument isn't going to make them go, oh yes, let's just make healthier food.
Giles YeoNo, no, no. Otherwise it would have done, if my argument works, it would have really solved it. So clearly, this is, this is living in a slightly idealized world, but we need to sort of conceptualize what is the framework within we can begin these discussions. I think, all
Nick Jikomesright, Professor, we've covered a lot. I. Thank you very much for your time. Very interesting stuff. Professor Yeo, thank you. Thank you for having me visit Mind and matter.substack.com. To find all of my content.
Send us Fan Mail At 93, Artemis Simopoulos explains why oils once used in paint now dominate the food supply, how a high omega-6 intake slows the making of EPA and DHA, and why cholesterol-lowering corn oil did not...
Send us Fan Mail Keith Baar explains why tendons stop adapting after 10 minutes of loading, why long low-load holds beat fast reps for connective tissue, and how vitamin C, collagen, caffeine and mTOR shape training....
Send us Fan Mail Dr. Stephen O'Rahilly explains GDF15, a stress hormone that makes us feel sick and eat less, and why morning sickness, and its severe form hyperemesis gravidarum (HG), comes from GDF15 made by the...
Send us Fan Mail Robin Carhart-Harris explains why his trial of psilocybin therapy vs. the SSRI escitalopram for depression missed one primary measure but favored psilocybin on almost everything else, and why SSRIs can...
Send us Fan Mail Nick talks with Prof. Gary Lewin (Max Delbrück Center, Berlin) about naked mole-rats, which in lab tests survived 18 minutes in pure nitrogen by shutting down brain activity, keeping the heart beating,...